The State Food and Drug Administration (SFDA) approved the registration application of Hualan Bio's Inactivated H1N1 Influenza A Vaccine (Split Virion) on September 4, 2009.

Compared with the adverse effects incidences showed in China seasonal influenza vaccine clinical trails, its adverse effects are within reach. Neither serious adverse events nor unexpected adverse trails happened.

The approved specifications include 15μg/0.5ml (vial) and 15μg/0.5ml (pre-filled syringe), which could be given safely for vaccination to people aged over 3 years old.